Login to Your Account



In The Clinic NEWS
'GERON' THE RIGHT STEM CELL TRACK?
With encouraging data from a phase I trial in amyotrophic lateral sclerosis (ALS) and a phase II trial under way testing NSI-566, Neuralstem Inc. has begun – with the same candidate – the first human neural stem cell study to be given the FDA's nod for chronic spinal cord injury.
Arrowhead Research Corp.'s shares (NASDAQ:ARWR) regained little ground Thursday after hitting a 52-week low at midweek as investors sold off shares over concern about the potential performance and timing of the company's experimental RNAi-based chronic hepatitis B (HBV) therapy, ARC-520.
Amgen Inc. put the biopharma world on notice by disclosing positive findings from the first phase III study evaluating efficacy and safety of its lead biosimilar candidate.
More In The Clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: